Compare · IRD vs NVO
IRD vs NVO
Side-by-side comparison of Opus Genetics Inc. (IRD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $184.18B, about 471.7x IRD ($390.5M).
- IRD has been more active in the news (17 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 14 for IRD).
- Company
- Opus Genetics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $390.5M
- $184.18B
- 1M return
- -
- +6.11%
- 1Y return
- -
- -14.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 17
- 8
- Recent ratings
- 14
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IRD
- SEC Form SCHEDULE 13G filed by Opus Genetics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.
- SEC Form SCHEDULE 13G filed by Opus Genetics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.
- SEC Form 10-Q filed by Opus Genetics Inc.
- Opus Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
- Chief Executive Officer Magrath George sold $110,184 worth of shares (28,258 units at $3.90), decreasing direct ownership by 1% to 2,010,636 units (SEC Form 4) to satisfy withholding tax
- Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S